Supplemental Figure 1. Study flow chart

Patients enrolled, N=119
- Excluded
  - menopause (n=5)
  - hormonal, antibiotic treatment or the use of intrauterine device < 6 months before the surgery (n=6)

Patients enrolled, N=108
- Excluded
  - endometriosis or other endometrial diseases (n=14)
  - uterine fibroids (n=7)
  - endocrine, immune or metabolic disease (n=1)
  - history of reproductive tract cancer (n=1)

Patients analyzed, N=85

Adenomyosis group, n=45
- Absent to Mild dysmenorrhea (n=26)
- Moderate to Severe dysmenorrhea (n=19)

Control group, n=40
- Cervical carcinoma in situ (n=28)
- Benign ovarian cyst (n=12)
Supplemental Figure 2. Quantitative analysis of the mean optical density (MOD) of PAI-1 between the proliferative phase and secretory phase.